Cramer Examines BioMarin Pharmaceutical

Cramer Examines BioMarin Pharmaceuticals

Jean-Jacques Bienaime, BioMarin Pharmaceutical CEO, discusses his company's efforts to develop treatment products for Lysosomal Storage Disorders. "We are the opposite of big pharma, we look at a significant improvement in a small patient population," says Bienaime.

On Tuesday, BioMarin Pharmaceutical CEO Jean-Jacques Bienaime appeared on “Mad Money” to talk about how his company develops and commercializes pharmaceutical products for lysosomal storage disorders.

Speaking with host Jim Cramer, Bienamie discussed the different drugs the company has on the market, as well as what’s to come. He also addressed the biotechnology space in general.

Watch the video to see the full interview.

Call Cramer: 1-800-743-CNBC

Questions for Cramer? [e-mail]

Questions, comments, suggestions for the Mad Money website? [e-mail]